0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-1041.55%PremiumMay 16, 2025Expiry Date4.56Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.10Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Sangamo Therapeutics Stock Discussion
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
We are proud to be showcasing our latest pipeline advances at ASGCT, including three platform presentations, reflecting our mission to develop innovative neurology genomic medicines to treat debilitating neurological diseases,” said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. “We are particularly excited to...
No comment yet